Navigating Safety, Efficacy & Delivery for Ocular Gene Therapies to Treat Complement-Mediated Retinal Diseases

• Exploring the critical need to prioritize complement targets with established clinical safety and efficacy profiles to mitigate the risks associated with sustained, irreversible therapeutic action
• Focussing on the complexities of achieving sufficient and consistent protein expression levels from gene therapy vectors to match the complement inhibition level seen with traditional biologics, particularly when targeting the immune-privileged organs like the eye
• Highlighting advancements and ongoing programs and explore how understanding complement biology can inform the design of more effective and targeted gene therapies

Speakers: